Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
An analysis of two leading weight-loss drug manufacturers projects that $10,000 invested equally between Eli Lilly and Novo Nordisk could grow to approximately $11,230 by end of 2027. Eli Lilly is experiencing strong momentum with 39% revenue growth and upcoming retatrutide filing, while Novo Nordisk is bouncing back with oral Wegovy success and the promising CagriSema candidate. Both companies are positioned to benefit from the fast-growing obesity treatment market.
